Cargando…

Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers

Despite surgical and therapeutic advances, glioblastoma multiforme (GBM) is among the most fatal primary brain tumor that is aggressive in nature. Patients with GBM have a median lifespan of just 15 months when treated with the current standard of therapy, which includes surgical resection and conco...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Ruijia, Wu, Cheng, Liu, Shiming, Zhao, Wenyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135425/
https://www.ncbi.nlm.nih.gov/pubmed/35612318
http://dx.doi.org/10.1080/10717544.2022.2075986
_version_ 1784713958499811328
author Liang, Ruijia
Wu, Cheng
Liu, Shiming
Zhao, Wenyan
author_facet Liang, Ruijia
Wu, Cheng
Liu, Shiming
Zhao, Wenyan
author_sort Liang, Ruijia
collection PubMed
description Despite surgical and therapeutic advances, glioblastoma multiforme (GBM) is among the most fatal primary brain tumor that is aggressive in nature. Patients with GBM have a median lifespan of just 15 months when treated with the current standard of therapy, which includes surgical resection and concomitant chemo-radiotherapy. In recent years, nanotechnology has shown considerable promise in treating a variety of illnesses, and certain nanomaterials have been proven to pass the blood–brain barrier (BBB) and stay in glioblastoma tissues. Recent preclinical research suggests that the diagnosis and treatment of brain tumor is significantly explored through the intervention of nanomaterials that has showed enhanced effect. In order to elicit an antitumor response, it is necessary to retain the therapeutic candidates within glioblastoma tissues and this job is effectively carried out by nanocarrier particularly functionalized nanocarriers. In the arena of neoplastic diseases including GBM have achieved great attention in recent decades. Furthermore, interleukin-13 receptor α chain variant 2 (IL13Rα2) is a highly expressed and studied target in GBM that is lacked by the surrounding environment. The absence of IL13Rα2 in surrounding normal tissues has made it a suitable target in glioblastoma therapy. In this review article, we highlighted the role of IL13Rα2 as a potential target in GBM along with design and fabrication of efficient targeting strategies for IL13Rα2 through surface functionalized nanocarriers.
format Online
Article
Text
id pubmed-9135425
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-91354252022-05-27 Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers Liang, Ruijia Wu, Cheng Liu, Shiming Zhao, Wenyan Drug Deliv Research Articles Despite surgical and therapeutic advances, glioblastoma multiforme (GBM) is among the most fatal primary brain tumor that is aggressive in nature. Patients with GBM have a median lifespan of just 15 months when treated with the current standard of therapy, which includes surgical resection and concomitant chemo-radiotherapy. In recent years, nanotechnology has shown considerable promise in treating a variety of illnesses, and certain nanomaterials have been proven to pass the blood–brain barrier (BBB) and stay in glioblastoma tissues. Recent preclinical research suggests that the diagnosis and treatment of brain tumor is significantly explored through the intervention of nanomaterials that has showed enhanced effect. In order to elicit an antitumor response, it is necessary to retain the therapeutic candidates within glioblastoma tissues and this job is effectively carried out by nanocarrier particularly functionalized nanocarriers. In the arena of neoplastic diseases including GBM have achieved great attention in recent decades. Furthermore, interleukin-13 receptor α chain variant 2 (IL13Rα2) is a highly expressed and studied target in GBM that is lacked by the surrounding environment. The absence of IL13Rα2 in surrounding normal tissues has made it a suitable target in glioblastoma therapy. In this review article, we highlighted the role of IL13Rα2 as a potential target in GBM along with design and fabrication of efficient targeting strategies for IL13Rα2 through surface functionalized nanocarriers. Taylor & Francis 2022-05-25 /pmc/articles/PMC9135425/ /pubmed/35612318 http://dx.doi.org/10.1080/10717544.2022.2075986 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Liang, Ruijia
Wu, Cheng
Liu, Shiming
Zhao, Wenyan
Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers
title Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers
title_full Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers
title_fullStr Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers
title_full_unstemmed Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers
title_short Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers
title_sort targeting interleukin-13 receptor α2 (il-13rα2) for glioblastoma therapy with surface functionalized nanocarriers
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135425/
https://www.ncbi.nlm.nih.gov/pubmed/35612318
http://dx.doi.org/10.1080/10717544.2022.2075986
work_keys_str_mv AT liangruijia targetinginterleukin13receptora2il13ra2forglioblastomatherapywithsurfacefunctionalizednanocarriers
AT wucheng targetinginterleukin13receptora2il13ra2forglioblastomatherapywithsurfacefunctionalizednanocarriers
AT liushiming targetinginterleukin13receptora2il13ra2forglioblastomatherapywithsurfacefunctionalizednanocarriers
AT zhaowenyan targetinginterleukin13receptora2il13ra2forglioblastomatherapywithsurfacefunctionalizednanocarriers